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PEPTIDE CONJUGATION OF BRANCHED AMPHIPHILIC PEPTIDE
CAPSULES
Baltazar Claro-Martinez, Susan Whitaker, John Tomich
Department of Biochemistry and Molecular Biophysics
Kansas State University

ABSTRACT

RESEARCH & RESULTS

In recent years, nanocarrier cellular therapy has been a rapidly
growing area for research in the treatment of malignant and
infectious diseases – most notably cancer. Conventional cancer
treatment has consisted of highly toxic, highly insoluble,
untargeted delivery of drugs that kill both cancerous and
healthy cells. Research in the Tomich lab consists of the
synthesis of Branched Amphiphilic Peptide Capsules (BAPCs),
which are self-assembling peptide nanospheres composed of
one or both of these branched peptide sequences: h5 and h9.
These peptides possess similar molecular characteristics of
phosphoglycerides but are synthesized chemically within the
lab. Previous publications by the Tomich group have
demonstrated that BAPCs are stabilized by hydrophobic
interactions and hydrogen bonds. Here, we further explore the
ability of BAPCs to retain their nanosphere shape and
encapsulated solutes at varying DMSO (dimethyl-sulfoxide)
concentrations (0%, 10%, and 25%) and pH (3.5, 7.5, 8.5) levels.
Using this framework, we will attach a short peptide to the
outside of the BAPCs using reversible disulfide linkages. This
coupling will be followed using Ellman’s reagent as a
quantitative measurement for reduced versus oxidized cysteines
and MALDI-TOF mass spectrometry. Data presented here will
show which conditions most favorably contribute to the
disulfide formation between the BAPC and the peptide in the
presence of DMSO. Upon cellular uptake, the reducing
environment of the cell’s interior will release the peptide. With
the changing face of diseases and medicine, the ability to attach
and encapsulate molecules of interest onto and within BAPCs
opens the door to many other therapeutic possibilities. This
suggests that BAPCs can be an attractive biocompatible carrier
for the delivery of various cancer therapy drugs.

Graph 1: Details Eosin-BAPCS encapsulation and fluoresce.

v

BACKGROUND
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BAPCs have demonstrated great
stability while having fine tuneavailability. These amphipathic particles
self assemble and form a functional
membrane like bilayer; Fig. 2, 3 –
composed of a hydrophobic outer
membrane and a hydrophilic inner
membrane. Their formation occurs
when two (15-20 residue) poly-cationic
peptides are mixed. Fig. 1 shows the
chemical structure of three usable
peptides. The ‘blue’ labeled lysine on all
represents a 90° segment common in
diacyl phospholipid.

Graph 2: H9-cysteine and Ellmans reagent under varying DMSO
concentrations.

Graph 4

Graph 2 and 3: Demonstrates three
different constituents which make the
graph. First, the initial points on the graph
belong to the blank absorbances at 412nm
for all our samples collected.
The next set of data points emphasize the
absorbance of our Ellmans reagent with
only pH buffer conditions (3.5,7.5,8.5).
Lastly, beginning at x=0, the peptides (H9Cys and Fleming) are introduced to the
Ellmans and pH buffer at varying
concentrations of DMSO at time intervals
Graph 3 of 1hour for 13 cycles.

Graph 4 and 5: Show
data from the MALDITOF mass spectrometry,
peaks of interest are
emphasized by being
boxed. Here, graph 4
shows that an
environment of pH 7.5 is
the minimum
requirement for
formation. Data
presented on these
graphs did not include
the addition of Ellmans
reagent.
Graph 5

DISCUSSION/INTERPRETATION
Fig. 2 Midsection BAPCs

Fig. 3 BAPC micelle

The first experimental procedure, regarding BAPCs containing the dye Eosin (2.1mM), was observed over a set temperature
where no fluorescence discrepancies were observed. Concluding that these BAPCS did not rapture and release the Eosin dye.
Knowing that BAPCS could retain Eosin, we then decided to run Eosin encapsulated BAPCS under 0%, 10%, and 25% DMSO – for
all pH values of 3.5, 7.5, and 8.5 respectively. Again, we were able to demonstrate that the BAPC was able to retain its shape
even at 25% DMSO. Graph 2 and 3 describe the H9-Cys peptide and Fleming peptide, both under DMSO condition and Ellmans
reagent. Here we are able to see how the Ellmans reagent affects the disulfide bonds and interacts with our peptide. Lastly,
from data collected on the MALDI-TOF we were able to detect noticeable differences not just from pH, but from DMSO variation
at our peak of interest ~3788.

METHODOLOGY
- Peptides were synthesized in lab by solid phase Fmoc
chemistry with clear amide being the starting resin.
- Concentrations were determined
by dissolving in 2,2,2trifluoroethanol and running
through the Varian 50 Bio UVSpectrophotometer (accounting for
phenylalanine).
- The CARY Eclipse fluorescence
spectrophotometer was used to
measure fluorescence. Beginning
with a 500 nm excitation
wavelength, followed by the
observation from 505 to 698nm
using a 0.3 cm quartz cuvette.
- During the hydration of the BAPCs, 1mM of each peptide was
combined and Eosin Y was added in a drop-wise manner.
- After hydrating for ~45 minutes, each solution was filtered
and centrifuged at 14,000 x g, in a weight cut off Eppendorf
filter of 30kDa to removed any external dyes.
- Filters were inverted and centrifuged at 2,000 x g, to collect
the BAPCs.
- The use of the Varian 50 Bio, was used for multiple scans.
- Samples were ran again under no Elllmans reagent and were
spotted under MALDI-TOF.
- Peaks of interest where further analyzed via mass
spectrometry and graphed.

FUTURE STUDIES
Our data reveled that a more basic solution is preferred in order
for reduction to take place. This being the case, future studies
would consist of testing different ions and their affects on BAPCs
stability. Other future work includes the identification of certain
unknown peaks in the MALDI-TOF analysis, as some adducts
would appear; such as sodium and potassium. Recognizing the
ability of water to permeate through the bilayer has also given
rise to other possible applications – such as water filtration in
developing countries, to the possible improvement of current
reverse osmosis techniques. The most important future plan,
however, is to successfully modify this delivery vehicle in order
to begin clinal trials.
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